Compare JSPR & GRDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | JSPR | GRDX |
|---|---|---|
| Founded | 2018 | N/A |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 26.3M | 28.6M |
| IPO Year | 2019 | 2016 |
| Metric | JSPR | GRDX |
|---|---|---|
| Price | $14.35 | $3.20 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 321.1K | 120.2K |
| Earning Date | 11-27-2026 | 11-27-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 19.22 | ★ 21.95 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.32 | $1.87 |
| 52 Week High | $17.03 | $6.93 |
| Indicator | JSPR | GRDX |
|---|---|---|
| Relative Strength Index (RSI) | 80.68 | 34.14 |
| Support Level | $0.64 | $2.35 |
| Resistance Level | $17.03 | $4.19 |
| Average True Range (ATR) | 1.05 | 0.78 |
| MACD | 1.15 | -0.23 |
| Stochastic Oscillator | 79.63 | 0.35 |
Jasper Therapeutics Inc is a clinical-stage biotechnology company focused on developing therapeutics targeting mast cell driven diseases such as Chronic Spontaneous Urticaria (CSU), Chronic Inducible Urticaria (CIndU) and asthma. The company's lead product candidate, briquilimab, is a monoclonal antibody designed to block stem cell factor (SCF) from binding to and signaling through the CD117 (KIT) receptor on mast and stem cells. The company has a single operating and reportable segment, which is the research and development of therapeutic products in the fields of chronic urticaria and asthma.
GridAI Technologies Corp, formerly known as Entero Therapeutics Inc, is a late clinical-stage biopharmaceutical company focused on the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases. The company's programs address unmet needs in GI health and include: latiglutenase, a Phase 3-ready, potentially first-in-class, targeted, oral biotherapeutic for celiac disease; capeserod, a selective 5-HT4 receptor partial agonist for indications including gastroparesis; and adrulipase, a recombinant lipase enzyme designed to enable the digestion of fats and other nutrients in cystic fibrosis and chronic pancreatitis patients with exocrine pancreatic insufficiency.